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Mersacidin is a tetracyclic lantibiotic with antibacte-
rial activity against Gram-positive pathogens. To
probe the specificity of the biosynthetic pathway of
mersacidin and obtain analogs with improved anti-
bacterial activity, an efficient system for generating
variants of this lantibiotic was developed. A satura-
tionmutagenesis library of the residues ofmersacidin
not involved in cycle formation was constructed and
used to validate this system. Mersacidin analogs
were obtained in good yield in approximately 35%
of the cases, producing a collection of 82 new com-
pounds. This system was also used for the produc-
tion of deletion and insertion mutants of mersacidin.
The outcome of these studies suggests that this
system can be extended to produce mersacidin
variants with multiple changes that will allow a full
investigationof thepotential useofmodifiedmersaci-
dins as therapeutic agents.
INTRODUCTION
The lantibiotics are a diverse group of highly modified peptides
produced by Gram-positive bacteria sharing the common feature
of (methyl)lanthionine ring structures (Sahl and Bierbaum, 1998).
Lantibiotics are derived from ribosomally synthesized peptides
that are subject to posttranslational modifications. Serine or thre-
onine residues are dehydrated to dehydroalanine (Da) or dehy-
drobutyrine (Db), respectively. These residues undergo Michael
addition with the thiol group of cysteine residues to form the char-
acteristic (methyl)lanthionine rings. Apart from these distinctive
rings, some lantibiotics also contain other modified residues or
ring structures, such as the 2-thioethenamine moiety in mersaci-
din (Chatterjee et al., 1992b) or epidermin (Allgaier et al., 1986),
the lysinoalanine ring and hydroxyaspartate in cinnamycin (Kess-
ler et al., 1987), D-alanine in lactocin S (Skaugen et al., 1994) and
lacticin 3147 (Ryan et al., 1999), an N-terminal oxobutyryl group in
Pep5 (Kellner et al., 1989) and lacticin 3147-A2 (Ryan et al., 1999),
and dihydroxyproline and chloro-tryptophan in microbisporicin
(Castiglione et al., 2008).
The biosynthetic pathways for a number of lantibiotics have
been cloned and sequenced, and functions have been inferred490 Chemistry & Biology 16, 490–498, May 29, 2009 ª2009 Elsevierfor the genes on the basis of homology with genes of known
function, gene disruptions, and enzymatic studies. As with other
antibiotics or secondary metabolites, the biosynthetic genes are
clustered together. The lantibiotic biosynthetic genes have been
given the generic locus name lan. They are specifically assigned
lanA for the gene encoding the lantibiotic prepeptide, lanB for the
gene encoding the enzyme responsible for serine or threonine
dehydration and lanC for the gene responsible for cycle forma-
tion. In some cases, the activities of LanB and LanC are housed
in a bifunctional enzyme encoded by lanM (Sahl and Bierbaum,
1998). The products of the lanP, lanT, and lanH genes are
involved in processing and/or transport of the prepeptide, and
lanI, lanE, lanF, and lanG encode for immunity or resistance.
Additional genes specific for particular features of some lantibi-
otics have been identified as well, such as lanD, which is respon-
sible for the oxidative decarboxylation of the C-terminal cysteine
of epidermin (epiD) (Kupke et al., 1992) or mersacidin (mrsD)
(Majer et al., 2002).
Mersacidin is a lantibiotic produced by Bacillus sp. HIL
Y-84,54728 at the late stages of growth and stationary phase
(Chatterjee et al., 1992a). The biosynthetic gene cluster contains
10 genes spanning 12.3 kbp. Mersacidin is a tetracyclic peptide
(Figure 1) containing 20 amino acid residues and is encoded by
mrsA as a prepeptide of 68 residues (Bierbaum et al., 1995). All
the genes in the cluster have been sequenced and the functions
have been identified (Altena et al., 2000). The mersacidin prepep-
tide MrsA is decarboxylated and oxidized by MrsD, producing
a 2-thioethenamine functionality at the C-terminal cysteine
(Majer et al., 2002). This modified MrsA is proposed to be the
substrate for MrsM that produces the tetracyclic structure,
which is processed and secreted by MrsT as the final bioactive
compound. There is a regulatory gene, mrsR1, which is respon-
sible for controlling the synthesis of MrsA (Guder et al., 2002),
and a two-component system, mrsR2/mrsK2, which encodes
for the sensor and kinase involved in the induction of the immu-
nity genes mrsE, mrsF, and mrsG (Guder et al., 2002).
Mersacidin has antibacterial activity against Gram-positive
pathogens; like vancomycin, it binds to the peptidoglycan
precursor lipid II (Brotz et al., 1995; Brotz et al., 1997). The results
of lipid II binding experiments with mersacidin in the presence of
vancomycin suggest that mersacidin binds to a different part of
the molecule (Brotz et al., 1998); hence, no cross-resistance
has been observed. Significantly, in vivo studies have shown
that mersacidin administered subcutaneously cures systemic
methicillin-resistant Staphylococcus aureus (MRSA) infectionsLtd All rights reserved
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vancomycin (Chatterjee et al., 1992b). Further studies have
shown that mersacidin also eradicates MRSA in a mouse rhinitis
model (Kruszewska et al., 2004). The activity of mersacidin
against MRSA makes it a potential candidate for development
as a therapeutic agent; therefore, information on the key residues
that contribute to the bioactivity and information on the flexibility
of the biosynthetic pathway would be very valuable for the design
of new molecules with improved properties. To probe the flexi-
bility of the mersacidin biosynthetic pathway, a systematic muta-
genesis study of the gene encoding for mersacidin and analysis of
the fermentation products of the mutants was performed, and the
results are presented below.
RESULTS
Construction of an Efficient System for Production
of Mersacidin Variants
A method for the construction of mersacidin variants has been
reported by Szekat et al. (2003). Using this method, it was
demonstrated that it is possible to generate variant mersacidin
molecules; however, this approach is laborious and involves
steps that are not suitable for obtaining large numbers of
mutants. To simplify the genetic manipulations required for the
construction of libraries of mersacidins, a trans complementa-
tion system was developed. This system consists of an inactive
mrsAmutant of the mersacidin producer organism and a comple-
menting shuttle plasmid capable of efficiently expressing mrsA
or its mutants. A simplified transformation procedure to deliver
this plasmid into the host by electroporation of demethylated
DNA was developed, facilitating the overall procedure and
making possible the generation of a large number of mutant
strains.
Figure 1. The Structure of Mersacidin and
Its Gene Cluster
(A) Primary structure of mersacidin indicating the
sequence and thioether bridge pattern.
(B) Organization of the mersacidin biosynthetic
gene cluster.
(C) Engineered system for generating mersacidin
mutants. Da, dehydroalanine; Ab, 2-aminobutyrate.
Host Strain forMersacidin Libraries
A mutant of the mersacidin producer strain
calledBacillus sp. TTEX, wherein the GAA
codon of the fourth amino acid of MrsA
was substituted for the stop codon TAA,
was used as a host (Schmitz et al., 2006).
This mutant does not produce MrsA and,
consequently, does not produce mersaci-
din. All the other genes in the mersacidin
pathway are functional.
Construction of aComplementation
and Expression Plasmid formrsA
A PCR product from base 4836 to base
5249 of the mersacidin gene cluster
(accession number AJ250862) containing
the promoter and leader peptide encoding sequence of mrsA
was obtained using the oligonucleotides jc7 and jc8 and the
plasmid pMER1 (Altena et al., 2000) as a template. The PCR
product was ligated to SmaI-digested pUC18. A plasmid with
the expected sequence and ligated in the orientation such that
the insert can be excised by digesting with EcoRI was selected
and designated pNB013. Plasmid pNB013 was digested with
EcoRI, and the 425-bp fragment was ligated to EcoRI-digested
pCU1 (Augustin et al., 1992). A plasmid with the expected
restriction pattern, where the 425-bp fragment can be excised
by digesting with EcoRI and not with SphI, was identified and
designated pNB014. This plasmid was digested with SphI and
HindIII, and the resulting 5.6-kbp fragment was ligated to the an-
nealed complementary oligonucleotides jc9 and jc10, encoding
for the mersacidin peptide with a silent mutation to create a BsrGI
site. Plasmids containing the newly introduced BsrGI site were
selected and sequenced. The plasmid with the expected
sequence was designated pNB018. This plasmid is a pCU1
derivative containing both the structural gene mrsA and its
promoter, modified such that the sequence encoding for mersa-
cidin can be removed or substituted. Digestion with SphI and
BsrGI enables the residues from 1 to 12 to be modified, whereas
digestion with BsrGI and HindIII allows the modification of resi-
dues 12–20. Multiple alterations of the entire region encoding
mersacidin can be introduced through digestion with SphI and
HindIII.
Complementation of Bacillus Sp. TTEX
A complementation test of Bacillus sp. TTEX with plasmid
pNB018 was performed to assess the production of mersacidin
when mrsA is complemented in trans. Plasmid pNB018 was
used to transform Escherichia coli ET12567 to obtain demethy-
lated plasmid. Electrocompetent Bacillus sp. TTEX wasChemistry & Biology 16, 490–498, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 491
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grown and tested for mersacidin production. Bacillus sp. TTEX
did not produce mersacidin, Bacillus sp. HIL Y-84,54728
produced 140–160 mg/l mersacidin, and the complementation
mutant produced 60–80 mg/l mersacidin. These results showed
that mersacidin production was restored in Bacillus sp. TTEX
when transformed with pNB018, indicating that the complemen-
tation system is a viable method for producing mersacidin
variants.
Construction of a Saturation Mutagenesis Library
of Residues Not Involved in Bridge Formation
The pattern of lanthionine bridges of mersacidin is conserved in
other lantibiotics, such as actagardine (Zimmermann et al.,
1995), michiganin A (Holtsmark et al., 2006), lacticin 3147-A2
(Ryan et al., 1999), plantaricin Wa (Holo et al., 2001), staphylo-
coccin C55a (Navaratna et al., 1998), haloduracin (McClerren
et al., 2006), and lichenicidin (Rey et al., 2004), suggesting that
it might contribute to the folding required for binding lipid II.
Taking this into consideration, a saturation mutagenesis library
was designed, keeping the residues involved in bridge formation
unchanged. Mutant plasmids targeting the 12 amino acids
that are not involved in lanthionine bridges were constructed
(Figure 1), making a collection of 228 (12 3 19) plasmids. Indi-
vidual plasmids were used to transform Bacillus sp. TTEX. Five
colonies from each transformation were grown and analyzed
for production of the corresponding mersacidin variant. Produc-
tion of the variants was evaluated by liquid chromatography-
mass spectrometry (LC-MS) and by antibacterial activity against
Micrococcus luteus. Figure 2 shows the outcome of the analysis
of fermentation samples of the 228 mutants. From this collection
of mutants, 82 were expressed and processed through to mature
mersacidins at high yields, as evidenced by detection of an ion
Figure 2. Mersacidin Substitution Library
Under the linear representation of mersacidin, the
circles indicate the variants that were detected by
LC-MS. Gray circles indicate variants produced at
high yield (>10%, versus mersacidin production),
and white circles indicate variants produced at
trace levels. Da, dehydroalanine; Db, dehydrobu-
tyrine; Ab, 2-aminobutyrate.
with the corresponding mass for a fully
processed mersacidin analog (Figure 2).
A set of 48 variants was produced at
trace level and was not further purified
for antimicrobial evaluation (Figure 2).
Production of mersacidin variants was
detected for each position tested, but
some positions, such as I19, E17, L14,
and P6, are less permissive, particularly
I19, where only the variant I19M was
produced at high yield. The central part
of ring B of mersacidin, from residues 7
to 11, is highly permissive to substitutions
allowing an average of more than 10
changes per residue.
Interestingly, mutants with cysteine replacing any of the resi-
dues in the mersacidin molecule were not detected. It is possible
that the introduction of a new cysteine would have led to scram-
bling of the ring structures, but there was no clear evidence
by LC-MS for production of molecules with altered numbers
of ring structures. In contrast, mutants incorporating serine or
threonine were produced at a number of positions. Serines or
threonines incorporated at positions 5 to 9 did not appear to be
dehydrated (though formally it cannot be ruled out that these
positions were dehydrated and other normally dehydrated moie-
ties were not), and these results agree with the finding that glycine
residues adjacent to serine in the lantibiotic lacticin 481 impair the
dehydration reaction of LctM in vitro (Chatterjee et al., 2006). In
contrast, both serine (introduced at position 10 or 11) and threo-
nine (introduced at position 10) were partially dehydrated. When
threonine was substituted for the normally dehydrated serine at
position 16, this appeared to be fully dehydrated.
Substitution of the Threonines Involved in Ring
Formation by Serines
Mutants in which the threonine residues involved in ring forma-
tion (positions 2, 4, 13, and 15) were substituted by serine
were constructed. Analysis of fermentation samples of these
mutants by LC-MS showed no evidence of lantibiotic produc-
tion. These types of substitutions have been productive for
several lantibiotic systems, including type I and type II classes,
so it is surprising that the mersacidin pathway was not permis-
sive for any of the four possible mutants. The dehydration of
serine would produce dehydroalanine, which is more reactive
than dehydrobutyrine, and in this system, it might form unnatural
bridging patterns by spontaneously reacting with cysteine. In
this case, as with all the other nonproductive mutants, it cannot
be ruled out that the new molecules are unable to autoinduce the492 Chemistry & Biology 16, 490–498, May 29, 2009 ª2009 Elsevier Ltd All rights reserved
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Mersacidin Librariesbiosynthetic pathway, leading to very low or undetected
amounts of the respective lantibiotic variant being produced.
Construction of an Insertion Library
An insertion library was constructed wherein each of the 20
possible amino acids was inserted at the N terminus and
between each pair of residues up to the end of ring B, between
V11 and C12 of mersacidin, making a collection of 240 plasmids
(12 3 20) (Figure 3). There were no attempts to introduce resi-
dues in ring C, because the size and sequence of this ring is
conserved in this class of lantibiotics and is believed to be
involved in binding to lipid II, although the presence of the equiv-
alent ring in haloduracin is not required for antibacterial activity
(Cooper et al., 2008). Individual plasmids were used to transform
Bacillus sp. TTEX. Five colonies from each transformation were
grown and analyzed for production of the corresponding variant
and for antibacterial activity. Figure 3 shows the outcome of
the analysis of fermentation samples of the 240 mutants. From
this collection of mutants, 37 were expressed and processed
through to mature mersacidins at high yields, as evidenced by
detection of an ion corresponding to the expected mass for a fully
processed mersacidin analog (Figure 3). Again, evidence was
found for production of other variants at much lower levels.
The N terminus of mersacidin was extended with glycine or
valine, but the new variants were produced only at trace levels.
None of the 20 amino acids could be inserted into ring A, indi-
cating that the biosynthetic machinery is specific for a two-
membered ring. Furthermore, the region between rings A and
B could not be extended with any of the insertions attempted.
The center of ring B was the most permissive area, as in the
substitution library. Insertions of polar and nonpolar residues
were well tolerated without an obvious pattern of preference
regarding chain length or charge, apart from the fact that neither
Figure 3. Mersacidin Insertion Library
Under the linear representation of mersacidin, the
arrows indicate the positions where residues were
inserted, and the circles indicate the insertion vari-
ants that were detected by LC-MS. Gray circles
indicate variants produced at high yield (>10%,
versus mersacidin production), and white circles
indicate variants produced at trace levels. Da,
dehydroalanine; Db, dehydrobutyrine; Ab, 2-ami-
nobutyrate.
proline nor aromatic amino acids were
accepted, with the exception of trypto-
phan between positions 4 and 5. As with
the substitution library, cysteine was not
incorporated. Serine was incorporated
after amino acids 8, 9, or 10 but did not
appear to be dehydrated. This is in
contrast to the G10S or V11S mutants in
which the newly introduced serine was
partially dehydrated.
Construction of Deletion Mutants
A collection of deletion mutants for each
position within ring B (positions 5–11)
of mersacidin was constructed. Again, no deletions were
attempted on ring C as it is believed to be involved in lipid II
binding. Individual plasmids were used to transform Bacillus
sp. TTEX. Five colonies from each transformation were grown
and analyzed for production of the corresponding variant. The
processing enzymes do not appear to tolerate any reduction in
the size of ring B, as no mature lantibiotics were detected
following LC-MS analysis of fermentation samples.
Antibacterial Activity of Mersacidin Variants
Partially purified fermentation samples from clones expressing
highly produced variants were assayed for antimicrobial activity
against M. luteus. Samples were fractionated to eliminate inter-
fering bioactive compounds produced by the host strain and
were bioassayed (see Supplemental Data available online).
Selected mersacidin variants with antibacterial activity against
M. luteus were produced at larger scale for quantitative studies
(2 l). The mersacidin variants were purified and assayed against
a panel of microorganisms to determine the MIC values. Table 1
shows the activity of selected compounds compared with that of
mersacidin.
All mersacidin variants with amino acid insertions showed
poor activity, compared with mersacidin. Eight variants showing
activity in preliminary screening against M. luteus were purified
for MIC determination, but none of these variants was active
against the target strains at a concentration of 64 mg/ml (data
not shown).
In contrast, many of the substitution variants retained signifi-
cant antibacterial activity. Mersacidin variants with antibacterial
activity are listed in Table 1. Some variation to the molecule was
tolerated at all of the positions tested except for L5, E17, and I19.
In most of the cases, mutants retaining appreciable activity
contained conservative amino acid changes, though someChemistry & Biology 16, 490–498, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 493
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Compound
S. aureus
SH1000a
S. aureus
R33 MRSA
S. epidermidis
NCTC11047
S. pneumoniae
BAA-255
M. luteus
ATCC4698
E. faecium
ATCC19579
E. faecalis
ATCC29212
E. faecium
7131121 VREb
Mersacidin 32 32 16,32 2 1,2 32 64 64
F3W 16 8 8 2,4 0.5 16 32 32
P6H 64 32,64 32,64 64, >64 16 >64 >64 >64
G7A >64 32,64 64 >64 64 64 >64 >64
G7N 64 16,32 32 16 < 4 64 >64 >64
G8H 64, >64 64 64 16 8 >64 >64 >64
G8N >64 16,32 64 >64 8 >64 >64 >64
G8Q >64 32 32,64 32,64 8 >64 >64 >64
G9A 32 8 32 8 < 4 64 >64 >64
G9H 32 8,16 32 16 < 4 64 >64 >64
G9S >64 64, >64 >64 >64 64 >64 >64 >64
G10A >64 64, >64 64, >64 8 8 >64 >64 >64
G10N >64 64, >64 >64 >64 8 >64 >64 >64
G10V >64 64, >64 64 16 < 4 >64 >64 >64
G10Y >64 64 8,16 < 4 < 4 64 32 >64
V11I 32 16 16 16 0.5 16 16 16
V11L 64 32 16 4,8 4,8 32 64 32
V11M 64 32 16,32 32 16 32 64 64
L14I 32 8 8,16 1 1,2 16 32 32,64
L14M 32 16 16,32 4 2 64 64 64
L14V 32 16 16 4 4,8 64 64 >64
S16A 64 16 32 4 2 32 64 >64
S16Db 32 8 16 32 1 32 32 64
S16G 32 16 16 2 2,4 32 64 64
MIC data are in mg/ml.
a Horsburgh et al. (2002).
b Vancomycin-resistant clinical isolate.nonconservative changes were tolerated in ring B (e.g., G7N,
G8Q, G9H, G10Y, and even P6H).
The variant F3W showed higher activity than did mersacidin
against most of the organisms tested. Variants G9A and G9H
showed activity comparable to that of mersacidin against Staph-
ylococcus, but lower activity against Streptococcus pneumoniae
and enterococci. Variants V11I, L14I and S16Db also showed
activity comparable to that of mersacidin against Staphylo-
coccus. L14I and S16Db also retained activity against entero-
cocci, whereas V11I had improved activity against these strains.
L14I also had promising activity against S. pneumoniae.
Representative variants with activity better than or compa-
rable to that of mersacidin were selected, and double mutants
combining the favorable mutations were constructed. The
double mutants F3W-L14I and V11I-L14I had activities compa-
rable to those of the parent mutants F3W and V11I, respectively,
but no additive effect was found.
DISCUSSION
Several studies have been performed to manipulate the structure
and biological activity of lantibiotics by site-directed mutagen-
esis of the lanA genes (Cotter et al., 2005). Specific mutations
for different lantibiotics are well tolerated in that new fully pro-494 Chemistry & Biology 16, 490–498, May 29, 2009 ª2009 Elseviercessed lantibiotics are synthesized, but others result in partially
processed lantibiotics or abolish production altogether. The first
systematic mutant analysis of a lantibiotic was performed using
the two-component lantibiotic lacticin 3147 (Cotter et al., 2006).
Alanine-scanning mutagenesis of this lantibiotic suggests that
there are particular areas within the peptides that are amenable
to changes and areas that are essential for production of the final
compound. Extensive investigations have also been performed
over a number of studies involving the lantibiotic nisin with similar
results (Rink et al., 2007b; Field et al., 2008).
The present study represents the most extensive and system-
atic exploration to date of the ability of the lantibiotic biosynthetic
machinery to tolerate changes to the primary amino acid struc-
ture of the propeptide. When a saturation mutagenesis library
of 228 mersacidin mutants was analyzed, we found that over
80 mutants produced mature mersacidin variants at good levels
(Figure 2). Undoubtedly, other mutants were produced, albeit at
lower production levels. This finding indicates a remarkable flex-
ibility in the lantibiotic biosynthetic machinery. In contrast, the
overall geometry of the lantibiotic appears to be under stricter
control. No deletions of amino acids in ring B were tolerated,
suggesting that this ring may have a minimum size. The equiva-
lent ring B of actagardine has six residues, compared with nine
for mersacidin, suggesting that the constraint may lie with theLtd All rights reserved
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sacidin peptide. Furthermore, no insertions into ring A or
between ring B and ring C were tolerated. Although insertions
into ring B were well tolerated, the number and range of amino
acids accepted was not as high as for substitutions, and produc-
tion of insertion variants decreased in positions close to the lan-
thionine bridge.
Ring B, especially amino acids 7–11, constitute a ‘‘hypervari-
able region’’ similar to the one identified in lacticin 3147-A2 for
the equivalent ring during alanine-scanning studies (Cotter
et al., 2006). As might be expected, conservative changes
were mostly tolerated, but nonconservative changes were also
successful. Indeed, other than the nonacceptance of cysteine,
there was little obvious pattern in terms of the acceptance or
otherwise of amino acid substitutions.
Analysis of 37 lantibiotic primary structures in a study by Rink
et al. (2005) showed that dehydratable serine and threonine
residues are more often flanked by hydrophobic (nonaromatic)
amino acids than by hydrophilic amino acids, and serine resi-
dues more often escape dehydration than threonine. These find-
ings have been experimentally supported for the nisin system
(Rink et al., 2007a). In the mersacidin system, the outcome
supports this study but only partially. At position 3 (flanking
two dehydrated amino acids), the hydrophobic amino acids
isoleucine and leucine and aromatic amino acids were accepted
as well as methionine, glutamine, and histidine, which are very
rarely seen as flanking amino acids in natural lantibiotics. Simi-
larly, at position 5, as well as the ‘‘expected’’ A, I, and V substi-
tutions, the residues M, S, F, and H were well tolerated. Other
than F, these amino acids are rarely seen C-terminal to dehy-
drated amino acids in natural lantibiotics, suggesting that the
mersacidin modification enzymes might have different substrate
specificities. At position 11, at the N-terminal side of a cysteine
residue, the results were more in line with the findings of Rink
et al. (2005). Perhaps it is important to point out that the
consensus of Rink et al. (2005) was obtained using class I and
class II lantibiotics combined, and the dehydratases for these
two classes have no sequence homology. For class II enzymes,
such as LctM, it has been reported that negatively charged flank-
ing residues do not prevent dehydration (Chatterjee et al., 2006).
For mersacidin in particular, the multiple concatenated rings in
the ring C part of the molecule can make interpretation rather
complex.
With regard to dehydration of introduced serines and threo-
nines, no difference between the two residues was noted except
that introduction of serine was perhaps more generally tolerated.
With the exception of position 16, where there is naturally a
dehydrated serine residue and an introduced threonine is fully
dehydrated (in poor concordance with the flanking amino acid
consensus of Rink et al., 2005), introduced serine or threonine
residues were not fully processed at high yield. Interestingly,
none of the ring-forming threonines could be replaced by serine,
suggesting high specificity for either the dehydration or ring-
forming machinery, although dehydration of serine at position
16 suggests that there is no specificity for threonine during dehy-
dration. As mentioned above, the more reactive dehydroalanine
might form lanthionine bridges spontaneously with cysteine resi-
dues, producing prepeptides that could inhibit any further step
of the pathway. It is surprising that these substitutions wereChemistry & Biology 16not productive since equivalent changes are tolerated in nisin
(Dodd et al., 1992) and in the in vitro synthesis system of lacticin
481(Chatterjee et al., 2006). Regarding the subsequent steps of
the pathway, the specificity of LctT (Furgerson Ihnken et al.,
2008) or NisT (Kuipers et al., 2004) do not seem to be limiting
steps so it is not expected to be for mersacidin. The secretion
and processing of misfolded MrsA mutants might take place,
but the accumulation of the final peptide in the medium
might be limited because of the action of proteases produced
by the host strain in these fermentation conditions. The develop-
ment of an in vitro synthesis system of mersacidin should clarify
this finding and will help to establish unequivocally whether
MrsM can differentiate serine-to-threonine substitutions in these
positions.
It appears that there are no simple rules to govern amino acid
acceptance. They may be different for each lantibiotic and modi-
fication enzymes and they may not be understandable from the
primary amino acid sequence but may require examination of the
secondary and tertiary structure of the peptides.
Interestingly, where no mature lantibiotic was observed, no
evidence was found for significant levels of partially processed
peptides. If the introduction of an amino acid causes failure
of a dehydration or cyclization step, it may be that the ‘‘mal-
formed’’ peptide fails to act as an inducer for the biosynthetic
apparatus because mersacidin induces its own production
(Schmitz et al., 2006). This could be avoided by adding mersaci-
din to the production medium but would complicate the evalua-
tion of the biological activity of the newly produced variants
because some would copurify with mersacidin. Alternatively,
molecules that are not fully cyclized may fail to be exported,
and their leader peptides might not be processed or may
fall subject to proteolysis, because Bacillus sp. are prolific
producers of proteases.
Indeed, apart from MrsM, which is responsible for lanthionine
formation, other enzymes implicated in tailoring (MrsD), cleavage
and export (MrsT), immunity, and regulation may constitute
further barriers to lantibiotic engineering. Van der Meer et al.
(1994) showed that, for the nisin biosynthetic machinery, dehy-
dration and export were remarkably tolerant of amino acid varia-
tion but that the leader sequence cleavage was quite specific.
A recent breakthrough in the in vitro synthesis of the lantibiotic
lacticin 481 using the isolated LctM enzyme offers the potential
to look directly at individual steps of the lantibiotic biosynthetic
pathways and to understand the parameters that control the
ability to manipulate the lantibiotic structure (Xie et al., 2004).
In this context, the low number of variants obtained at position
I19 might be explained by its proximity to C20, because this
residue is the substrate for the oxidative decarboxylation reaction
of MrsD, the first step in the modification of MrsA (Majer et al.,
2002). It seems likely that the specificity of MrsD limits the
productivity of variants at this position. No insertions were well
tolerated at the N terminus, probably as the result of interference
with processing of the leader peptide or, possibly, as the result of
subsequent proteolysis. We are currently attempting to establish
an in vitro system for mersacidin biosynthesis. Only in vitro
studies will ultimately allow dissection of the roles of different
elements of the biosynthetic machinery and, eventually, the over-
coming of intrinsic limitations, perhaps by mutation and evolution
of the biosynthetic machinery., 490–498, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 495
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Strain or plasmid Use Source
Bacillus sp. HIL Y-8,54728 Mersacidin producer Chatterjee et al., 1992a
Bacillus sp. TTEX Host for mersacidin library Schmitz et al., 2006
Escherichia coli DH10B Cloning host Invitrogen
E. coli ET 12567 Host for demethylated DNA MacNeil et al., 1992
Micrococcus luteus ATCC4698 Bioassay for mersacidins ATCC
pMER1 Template for PCR Altena et al., 2000
pUC18 E. coli cloning vector Yanisch-Perron et al., 1985
pCU1 E. coli-Bacillus shuttle Augustin et al., 1992
pNB013 Intermediate for mrsA expression This work
pNB014 Intermediate for mrsA expression This work
pNB018 mrsA and variants expression This work
Oligonucleotide Sequence (50-30)
Jc7 CTTATGAGAATTCGAGACAAGGTAAACT
Jc8 GCATGCTGCTTCCATGTCTCCCGCACCTACT
Jc9 CACTTTTACATTGCCTGGTGGCGGCGGTGTTTGTACACTAACTTCTGAATGTATTTGTTA
Jc10 AGCTTAACAAATACATTCAGAAGTTAGTGTACAAACACCGCCGCCACCAGGCAATGTAAAAGTGCATGWith regard to the activity of mersacidin variants, it was
apparent that any change in the overall geometry of the lantibi-
otic-like insertion of new amino acids essentially abolished anti-
bacterial activity. It would appear from this result that the overall
geometry of the molecule has been evolved for a very precise
interaction with lipid II. However, it is interesting in this context
that other lipid II-binding lantibiotics of the mersacidin class
have profoundly different overall geometries, with only ring C as
the highly conserved part of the molecule. Given the high degree
of conservation of ring C in the mersacidin class of lantibiotics, it
is not surprising that only conservative changes at position L14
produced compounds with activity comparable to that of mersa-
cidin, because this position is highly conserved. Tolerance to
changes at position 16 would be less surprising because this
position does seem to vary, being dehydroalanine for mersacidin,
I for actagardine, H for lacticin 3147, and K for lichenicidin. Our
results concur with the findings of Szekat et al. (2003) in that
the glutamate at position 17 appears to be essential for activity.
The equivalent Glu residue in haloduracin has been substituted
for alanine or glutamine, and antibiotic activity is abolished
(Cooper et al., 2008). Regarding the conservation of ring C in
this type of lantibiotic, it has been shown that when the equivalent
ring in lacticin 3147 was opened, bioactivity was abolished
(Cotter et al., 2006; Field et al., 2007), but for haloduracin, the
compound was synthesized and surprisingly maintained antibac-
terial activity (Cooper et al., 2008). This study suggests that the
sequence conservation might be important for binding lipid II
but that the lanthionine bridge is not essential for bioactivity;
perhaps the folding of the final products might be different
when they are synthesized in vivo, or the contribution of the
second peptide in the folding of the final antibiotic might be
important for this ring. Significantly, the results presented here
do indicate that it is possible to obtain novel mersacidin variants
with improved antibacterial activity by engineering of the primary
amino acid structure. Variant molecules with improved overall
bioactivity, such as F3W, offer significant potential for develop-
ment of therapeutic agents.496 Chemistry & Biology 16, 490–498, May 29, 2009 ª2009 ElsevierSIGNIFICANCE
This study is the most extensive mutagenesis analysis per-
formed on a lantibiotic and was achieved using an efficient
trans complementation system to generate mersacidin
mutants in the producer strain. A high number of newmersa-
cidin molecules were generated showing that the biosyn-
thetic pathway of this lantibiotic has relaxed specificity.
Ring A of mersacidin and its flanking residues cannot be
extended. Ring B is particularly amenable to substitutions
and insertions with conserved and nonconserved residues,
but the positions adjacent to the bridge-forming residues
within this ring tend to be more stringent. Surprisingly, dele-
tions were not tolerated in ring B. Mersacidin contains
methyl-lanthionine bridges only, and mutants encoding
for mersacidin variants with lanthionine bridges were not
productive. The antibacterial activity of the new molecules
was assessed, and most of the newly formed compounds
were inactive or showed less potency than did mersacidin,
but compounds with improved activity against different
Gram-positive pathogens were identified, suggesting that
an improvement program in this type of compounds can
be performed using this methodology.
EXPERIMENTAL PROCEDURES
Strains, Plasmids, Oligonucleotides, Culture Conditions,
and DNA Manipulations
The strains, plasmids, and oligonucleotides used for genetic manipulations
and production of mersacidins are described in Table 2. E. coli cultures
were grown at 37C in Luria broth (LB) or Luria agar (LA) supplemented with
the appropriate antibiotic. Bacillus cultures were grown in tryptic soy broth
(TSB), tryptic soy agar (TSA), or LA at 30C supplemented with the appropriate
antibiotic. The composition of mersacidin production medium is 50 mM
(NH4)2SO4, 2 mM MgSO4, 1 mM CaCl2.7H2O, 0.2 mM FeSO4.7H2O, 1 mM
MnSO4.H2O, 1 M potassium phosphate buffer (pH 7.0; 40 ml/l); 1 M Tris mal-
eate buffer (pH 7.0; 100 ml/l), and 400 mM glucose added after sterilization.
PCR was performed using a Robocycler Gradient 96 (Stratagene) and Pfu
polymerase (Promega). The reaction conditions were as follows: Cycle 1,Ltd All rights reserved
Chemistry & Biology
Mersacidin Libraries95C for 3 min, 45C for 1 min, and 72C for 1 min; and cycles 2–26, 95C for 1
min, 45C for 1 min, 72C for 1 min, and a further incubation step at 72C for
10 min. Site-directed mutagenesis to obtain plasmids encoding for mersacidin
variants was performed using the method ExhauSeq (Delcourt, 2006) together
with pNB018 as a template.
Electroporation of Bacillus Sp. TTEX
Bacillus sp. TTEX was transformed by electroporation using a modification of
the method described by Xue et al. (1999). Bacillus sp. TTEX was used to inoc-
ulate 10 ml of LB, and the culture was incubated at 30C and 250 rpm for 16 hr.
An aliquot of 3 ml of this culture was used to inoculate 50 ml of TSB with
sorbitol and mannitol (both to 0.5 M final concentration) in a 250-ml conical
flask. This culture was grown at 30C and 250 rpm for 4.5 hr (OD600 = 2.0).
The culture was cooled on ice for 10 min before centrifuging at 2,500 rpm
for 30 min. The cell pellet was resuspended in 6 ml of ice-cold electroporation
medium (10% glycerol in 1 M sorbitol, and 0.75 M mannitol) and was centri-
fuged for 3 min at 134003 g. The cells were washed three times with 3 ml of
ice-cold electroporation medium (with centrifugation for 3 min at 134003 g)
before finally resuspending in 1 ml of ice-cold electroporation medium.
Aliquots of 60 ml were used for electroporation, either immediately or after
storage at80C. Demethylated plasmid DNA (500–1000 ng in 1.5 ml) obtained
from E. coli ET12567 was added to electrocompetent cells and transferred to
a precooled 1 mm gap electroporation cuvette. The voltage used was 2500 V
on an electroporator preset for 10 mF capacitance and 600 U resistance.
Following electroporation, 1 ml of recovery medium was added (TSB with 1 M
sorbitol and 0.75 M mannitol final concentration), and the suspension was
transferred to a 1.5-ml centrifuge tube and incubated at 30C for 3 hr. After
centrifugation at 134003 g for 3 min, the pellet was resuspended in 200 ml
of TSB and plated on LA containing the appropriate antibiotic for selection.
Fermentation Conditions of Bacillus Sp. HIL Y-84,54728
and Mutants for Production of Mersacidin
Bacillus sp. HIL Y-84,54728 or mutant colonies were transferred to 15-ml
culture tubes containing 3 ml of TSB (supplemented with 25 mg/l chloram-
phenicol [Cm] for complementation mutants). These seed cultures were incu-
bated at 30C and 250 rpm for 24 hr; an aliquot of 0.5 ml of each culture was
used to inoculate 50-ml conical flasks containing 10 ml of mersacidin produc-
tion medium (supplemented with 25 mg/l Cm for complementation mutants).
The cultures were incubated at 30C and 250 rpm for 5 days. For large-scale
fermentations, seed cultures were grown in 250-ml conical flasks containing
50 ml of TSB with 25 mg/l Cm. Cultures were incubated at 250 rpm and
30C for 24 h, an aliquot of 20 ml of seed culture was used to inoculate 2-l
conical flasks containing 500 ml of production medium with 25 mg/l Cm.
The cultures were incubated at 30C and 250 rpm for 5 days.
Detection and Evaluation of Mersacidin by Bioactivity
Antibacterial activity of fermentation samples or purified samples was deter-
mined by Mueller-Hinton Agar diffusion bioassays using M. luteus ATCC
4698 as the indicator strain. Susceptibility testing (minimum inhibitory concen-
tration [MIC]) for all aerobic organisms, with the exception of S. pneumoniae,
was performed following the recommendations of CLSI. Susceptibility testing
of S. pneumoniae was performed by two-fold serial dilutions in brain-heart-
infusion broth supplemented with 50 mg/ml Ca2+. Vancomycin was used as
a reference antibiotic, and plates were incubated aerobically, with shaking,
for 18–20 hr at 37C with the MIC defined as the lowest concentration of
drug that prevented visible growth.
Detection of Mersacidin Variants by LC-MS
Fermentation samples were spun down at 34503 g for 10 min in 15-ml centri-
fuge tubes. The supernatants were transferred to 50-ml centrifuge tubes con-
taining 100 mg of conditioned resin Diaion HP-20 (Supelco). After incubation at
room temperature for 6 h with shaking, the supernatants were discarded, and
the resin containing the bound mersacidin variant was washed twice with 10 ml
of water. Two further washing steps were performed with 10 ml of methanol:
water (1:1). Mersacidin variants were eluted from the resin with 1 ml of 100%
methanol. The eluates were dried down, resuspended in 250 ml of methanol:
water (1:1), and analyzed by LC-MS, high-performance liquid chromatography
(HPLC), and bioassay. Samples of 20 ml were analyzed by LC-MS using theChemistry & Biology 16HPLC gradient conditions listed in Supplemental Data. Mass spectrometry
conditions and the procedure for fractionation of fermentation samples to elim-
inate background antibiotic activity are listed in Supplemental Data. Mersacidin
variants were isolated using the methods described in Supplemental Data.
SUPPLEMENTAL DATA
SupplementalData include three tablesandcanbe foundwith thisarticleonlineat
http://www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00144-6.
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